{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026929","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.758899+00:00","generated_at":"2026-06-20T23:59:55.977363+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"HeartSciences targets FDA De Novo resubmission around fiscal year end; cash $3.1M","bullets":["Patient enrollment for MyoVista pivotal study near completion; resubmission target around April 2023 fiscal year-end.","Cash and cash equivalents $3.1M as of Oct 31, 2022; sufficient through FDA resubmission.","No meaningful revenue in Q2 fiscal 2023 as development-stage company.","Entered multi-year collaboration with Rutgers University for AI algorithm development.","AMA issued new Category III CPT codes covering AI assistive ECG risk assessments for cardiac dysfunction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026929","json":"https://secwatch.observer/filing/0000950170-22-026929.json","markdown":"https://secwatch.observer/filing/0000950170-22-026929.md","text":"https://secwatch.observer/filing/0000950170-22-026929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/0000950170-22-026929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/hscs-20221222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:59:55.977363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"643749411675110348f0a06eee1459d8edcd9be0","claim":"HeartSciences Inc. reported financial results for the fiscal 2023 second quarter ended October 31, 2022.","evidence_excerpt":"On December 16, 2022, Heart Test Laboratories, Inc. (the \"Company\") issued a press release providing information regarding the Company's financial and operating results for the quarter ended October 31, 2022, and other business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/0000950170-22-026929-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal 2023 second quarter ended October 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}